JPMorgan Chase & Co. increased its holdings in shares of PetMed Express, Inc. (NASDAQ:PETS) by 213.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,499 shares of the company’s stock after acquiring an additional 24,844 shares during the quarter. JPMorgan Chase & Co. owned about 0.18% of PetMed Express worth $1,215,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Pinebridge Investments L.P. boosted its position in PetMed Express by 1.0% during the second quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock worth $110,000 after acquiring an additional 27 shares during the last quarter. Acrospire Investment Management LLC purchased a new position in PetMed Express during the second quarter worth about $110,000. Sei Investments Co. raised its stake in PetMed Express by 50,142.9% during the third quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock worth $117,000 after purchasing an additional 3,510 shares during the period. Fred Alger Management Inc. purchased a new position in PetMed Express during the second quarter worth about $162,000. Finally, Thompson Siegel & Walmsley LLC purchased a new position in PetMed Express during the third quarter worth about $149,000. Hedge funds and other institutional investors own 99.88% of the company’s stock.
A number of equities analysts have commented on PETS shares. Northcoast Research set a $58.00 target price on shares of PetMed Express and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Noble Financial reaffirmed a “hold” rating on shares of PetMed Express in a research note on Friday, October 27th. Zacks Investment Research raised shares of PetMed Express from a “sell” rating to a “hold” rating and set a $50.00 target price on the stock in a research note on Friday, October 20th. ValuEngine downgraded shares of PetMed Express from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. Finally, BidaskClub raised shares of PetMed Express from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $42.80.
In other news, Director Ronald J. Korn sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were sold at an average price of $35.57, for a total value of $35,570.00. Following the sale, the director now directly owns 73,833 shares of the company’s stock, valued at approximately $2,626,239.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gian Fulgoni sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $44.38, for a total transaction of $887,600.00. Following the completion of the sale, the director now directly owns 55,900 shares in the company, valued at $2,480,842. The disclosure for this sale can be found here. 4.00% of the stock is currently owned by insiders.
PetMed Express, Inc. (PETS) opened at $51.68 on Friday. PetMed Express, Inc. has a 52 week low of $19.21 and a 52 week high of $52.20. The company has a market cap of $1,060.00, a PE ratio of 34.68, a price-to-earnings-growth ratio of 2.87 and a beta of 1.12.
PetMed Express (NASDAQ:PETS) last issued its earnings results on Monday, October 23rd. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.13. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. The company had revenue of $66.70 million for the quarter, compared to the consensus estimate of $63.41 million. During the same period in the previous year, the firm earned $0.24 earnings per share. PetMed Express’s quarterly revenue was up 9.7% compared to the same quarter last year. analysts predict that PetMed Express, Inc. will post 1.68 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/12/jpmorgan-chase-co-acquires-24844-shares-of-petmed-express-inc-pets.html.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.